Last reviewed · How we verify
ER OROS paliperidone, paliperidone ER — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ER OROS paliperidone, paliperidone ER (ER OROS paliperidone, paliperidone ER) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ER OROS paliperidone, paliperidone ER TARGET | ER OROS paliperidone, paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ER OROS paliperidone, paliperidone ER CI watch — RSS
- ER OROS paliperidone, paliperidone ER CI watch — Atom
- ER OROS paliperidone, paliperidone ER CI watch — JSON
- ER OROS paliperidone, paliperidone ER alone — RSS
Cite this brief
Drug Landscape (2026). ER OROS paliperidone, paliperidone ER — Competitive Intelligence Brief. https://druglandscape.com/ci/er-oros-paliperidone-paliperidone-er. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab